TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01186328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EZN-3042
Description: Dose will be assigned at study entry. To be given as a 2 hour intravenous infusion on days -5, -2, 8, 15, 22 and 29. Dose levels: L0 (level zero): 1.5 mg/kg, L1: 2.5 mg/kg, L2: 5 mg/kg, L3: 6.5 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given intrathecally on day -6. Patients who may have received intrathecal chemotherapy within 7 days of day 0 as part of their prior maintenance chemotherapy (e.g. before the diagnosis of relapse) or as part of the diagnostic workup will not receive this dose of IT cytarabine. If given, dose is defined by age:~1-1.99 years: 30 mg 2-2.99 years: 50 mg~Greater than or equal to 3 years: 70 mg.~Cytarabine is also part of the triple intrathecal therapy given to CNS 3 patients on Days 8, 15, 22 and 29. Dose is defined by age:~1. - 1.99 years: 16 mg~2. - 2.99 years: 20 mg~3. - 8.99 years: 24 mg~Greater than or equal to 9 years: 30 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2/day given intravenous infusion (IV) over 15 minutes on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40 mg/m2/day divided BID or TID given orally on days 1 through 29. For patients who are unable to tolerate prednisone orally, substitute IV methylprednisolone at 80% of the oral prednisone dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/m2/day (maximum dose 2 mg) given intravenous push over 1 minute or infusion via mini-bag as per institutional policy on days 1, 8, 15 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase
Description: 2500 IU/m2 intramuscular injection on days 2, 9, 16, 23. If available, Erwinia L-asparaginase may be substituted for pegaspargase in patients with clinically significant prior allergies to pegaspargase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intrathecally to patients with CNS1 or CNS2 disease at the dose defined by age below on days 15 and 36:~1-1.99 years: 8 mg 2-2.99 years: 10 mg 3-8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg~Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:~1. - 1.99 years: 8 mg~2. - 2.99 years: 10 mg~3. - 8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:~1. - 1.99 years: 8 mg~2. - 2.99 years: 10 mg~3. - 8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg
Study: NCT03047174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mepitel® Film
Description: Mepitel® Film is a gentle, sterile, transparent, breathable film dressing consisting of polyurethane film coated with a special contact layer. The film dressing is supported with a paper frame for ease of application. Mepitel® Film is an ultra thin, transparent, breathable soft silicone film dressing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Cream: Fatty cream with 2-5% urea is applied to the irradiated skin 3-4 times daily.~Mometasone furoate cream: In addition to the fatty cream with 2-5% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily.
Study: NCT01060020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Single oral dose of 40mg or 80mg of Sildenafil
Study: NCT04424290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764524
Description: BI 764524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764524
Description: BI 764524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764524
Description: BI 764524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764524
Description: BI 764524

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham control of BI 764524
Description: Sham control of BI 764524
Study: NCT01265641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981, 2000mg
Description: Single oral dose, tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981, 200mg
Description: Single oral dose, tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin, 400mg
Description: Single oral dose, capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose, tablets
Study: NCT04854538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ekmasonid
Description: 1 extended release tablet contains 9 mg Budesonide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uceris (first dose)
Description: 1 extended release tablet contains 9 mg Budesonide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uceris (second dose)
Description: 1 extended release tablet contains 9 mg Budesonide
Study: NCT03393403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 0.5mcg/kg intravenous(IV)continuous infusion for 30 minutes, or 0.5mcg/kg adding to local anesthetic for subcostal TAP block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 0.5mcg/kg intravenous(IV)continuous infusion for 30 minutes, or 0.5mcg/kg adding to local anesthetic for subcostal TAP block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Sodium-chloride
Description: 0.125ml/kg intravenously infusion in Dexmedetomidine_adj group and control group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% Sodium-chloride
Description: 0.125ml/kg intravenously infusion in Dexmedetomidine_adj group and control group
Study: NCT03129711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glazed Celtra Duo
Description: zirconia reinforced lithium silicate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IPS Empress CAD
Description: Standard etchable glass ceramic for laminate veneers
Study: NCT02299505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceritinib
Description: The investigational drug ceritinib was supplied to the Investigators as 150 mg capsules, for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceritinib
Description: The investigational drug ceritinib was supplied to the Investigators as 150 mg capsules, for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceritinib
Description: The investigational drug ceritinib was supplied to the Investigators as 150 mg capsules, for oral administration.
Study: NCT03181243

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Madajet
Description: The spermatic cord is firmly trapped between the middle finger, index finger and thumb of the left hand. The injector's sheath is placed over the spermatic cord with gentle pressure adjacent to the external inguinal ring. Depending upon the thickness of spermatic cord, three or four injections are consecutively administered around it, beginning from proximal to distal points.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Needle injection
Description: The pubic tubercle is palpated on the side that is going to be blocked. The spermatic cord is then immobilised with the non-dominant hand between the thumb and index finger. Right after needle puncture with attached syringe and local anaesthetic solution is conducted at a point that is 1 cm inferior to and 1 cm medial to the pubic tubercle, pass the needle directly downward in a vertical fashion, which leads it into the spermatic cord. After a check-up (negative aspiration) for bleeding, approximately 3 mL of solution (Lidocaine 2%) is injected into the cord.
Study: NCT00869557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stribild
Description: Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR once daily (QD) + placebo to match Atripla once daily prior to bedtime (QHS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atripla
Description: Atripla (EFV 150 mg/FTC 200mg/TDF 300 mg) STR QHS + placebo to match Stribild QD
Study: NCT00416793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03583905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330
Description: CKD-330 Tab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CKD-330
Description: CKD-330 Tab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of CKD-330
Description: Placebo of CKD-330 Tab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D086
Description: D086 Tab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: D086
Description: D086 Tab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of D086
Description: Placebo of D086 Tab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: D723
Description: D723 Tab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of D723
Description: Placebo of D723 Tab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of D723
Description: Placebo of D723 Tab.
Study: NCT03241433

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval training
Description: exercise by use of stationary cycles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity continuous training
Description: exercise by use of stationary cycles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Exercise
Description: no exercise training will be given and no exercise will be added to subjects routine
Study: NCT01559688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accelerated Resolution Therapy (ART)
Description: ART is a cognitive based therapy which integrates an eye movement technique while focusing on a problem (traumatic experience) during the therapy session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist
Description: Fitness assessment or career counseling
Study: NCT00519792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega DUROS device
Description: Omega DUROS device 25mcg inserted SC for 48 weeks Omega DUROS device 50mcg inserted SC for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega DUROS device
Description: Omega DUROS device 25mcg inserted SC for 48 weeks Omega DUROS device 50mcg inserted SC for 48 weeks
Study: NCT03245190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiauranib
Description: 50mg, orally once daily
Study: NCT01313351

Intervention type: DEVICE
Intervention: RPS InflammaDry Detector™
Description: A noninvasive immunoassay for detecting MMP-9 levels in tears
Study: NCT02928146

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hernia Repair
Study: NCT03862209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community mental health team
Description: CMHT will provide home-based treatment inclusive of crisis resolution services and procedures for early recognition of subclinical psychosis and bipolar disorder, and intensive case management. Integrated care (i.e. health and social care interventions) will be provided to all clients. Furthermore, health and social care evidence-based interventions for severe mental illness (SMI) will be employed during home treatment, such as family-based interventions, motivational interviewing, and cognitive behavioural therapies, combined with medication management and identifying employment (paid and non paid options) and support in finding and maintaining this employment, recovery groups and housing opportunities.
Study: NCT02928146

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hernia Repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hernia Repair
Study: NCT04177888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hot Pack
Description: It is a single-use pack filled with magnesium sulfate and water, which was squeezed between the hands to activate their warming effect. The temperature ranges between 40°C to 50°C, which is safe to use. Thus, it provided a consistent heat therapy for up to 30 minutes. They can be used directly on the skin or covered with gauze to avoid direct skin contact. Applied to the lower back area for 30 minutes, followed by 10 minutes rest between each hot pack application, then it was reapplied for another 30 minutes. This procedure was repeated till delivery.
Study: NCT01796314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Educational Program
Description: The intervention is a therapeutic educational programme as recommended in the care of Alzheimer's disease. It includes two consultations for the dyad AD patient/caregiver and four group sessions, one a week, for caregivers only. The intervention length is 2 months.~These collective sessions focus on :~1. Knowledge of the disease~2. Pharmacological and non pharmacological treatments. Behavioural and psychological symptoms of dementia~3. Crisis situations. Prevention of caregiver's exhaustion~4. Assistive devices and care pathways.~Monitoring will consist of a two consultations to 6 and 12 months including assessment of secondary outcome measures.
Study: NCT00727987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 148
Description: 50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 152.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: 6 mg/week to 8 mg/week taken orally (by mouth) from at least 4 weeks before the initial investigational treatment to the completion of assessment at Week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: 6 mg/week to 8 mg/week taken orally (by mouth) from at least 4 weeks before the initial investigational treatment to the completion of assessment at Week 52.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate (MTX)
Description: 6 mg/week to 8 mg/week taken orally (by mouth) from at least 4 weeks before the initial investigational treatment to the completion of assessment at Week 52.
Study: NCT00189527

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: respiratory settings

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: respiratory settings
Study: NCT04023305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep sedation by Sevoflurane on the Morphotype of ARDS in ICU patieNts
Description: Pharmacokinetic of inhaled sevoflurane used for sedation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep sedation by Sevoflurane on the Morphotype of ARDS in ICU patieNts
Description: Pharmacokinetic of inhaled sevoflurane used for sedation
Study: NCT04229199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: simulation
Description: Dyads allocated to the IG were taken into a tour to a simulation operating room accompanied by an expert anesthesia technologist two weeks before the day of surgery. This simulation operating theater is a real operating room equipped with a surgical trolley, sealing surgical lights, anesthesia machine, vital signs monitor, stethoscope, surgical trays, surgical sink, and gas supply pendent. It was prepared with popular cartoon characters, child manikin, and face masks connected to the anesthesia circuit and re-breathing bag. After being assessed by anesthesia clinic doctors, children and their parents in the IG were given a chance to visit the simulation operating room, to receive orientation, education, and demonstration orientation about what they are going to experience in the operating room. Children were encouraged to apply vital signs monitoring, and to simulate providing mask anesthesia induction to a child manikin.
Study: NCT01492101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-102
Description: 145 mg/m2 NKTR-102 will be delivered q21day as a 90-minute intravenous (IV) infusion on day 1 of each treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of Physician's Choice (TPC)
Description: One of the following Treatment of Physician Choice will be administered per standard of care:~eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel
Study: NCT00374088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Loading dose: Subjects randomized to IV NAC will receive a total loading dose of 100 mg/kg of 10% (100 mg/mL) solution. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the loading dose will be 1 mL/kg, anticipated to be 2.5-5 mL in our patient population. The loading dose will be administered over 1 hr beginning 1 hr prior to the patient's OR time. Subjects in the placebo group will receive 1 mL/kg of D5W over 1 hr.~Maintenance infusion: Subjects randomized to IV NAC will receive an infusion of 10 mg/kg/hr of 10% (100 mg/mL) solution for 24 hrs, starting in the OR after weaning from CPB. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the maintenance infusion will be 0.1 mL/kg/hr, anticipated to be 0.25-0.5 mL/hr in our patient population. Subjects in the placebo group will receive 0.1 mL/kg/hr of D5W for 24 hrs.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: D5W bolus prior to surgery and D5W infusion after surgery in an equal volume to the drug arm.
Study: NCT04622475

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant (FMT) Capsule
Description: When enrolled in the study, subjects will ingest 20 FMT capsules/day orally for 3 consecutive days. If the syndrome is not completely recovered or relapse 14 days after the first administration, the subject will receive a booster dose (20 capsules/day for 3 consecutive days).
Study: NCT01588366

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally
Study: NCT04077814

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foot Drop Stimulatio - Neuro Orthosis
Description: Walkaide is the Foot drop stimulator (FDS) on the peroneal nerve provides active dorsiflexion of muscle during the swing phase of gait.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foot Drop Stimulatio - Neuro Orthosis
Description: Walkaide is the Foot drop stimulator (FDS) on the peroneal nerve provides active dorsiflexion of muscle during the swing phase of gait.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct brain stimulation
Description: Transcranial direct brain stimulation on motor cortex
Study: NCT05022290

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-syringe diluted with normal saline technique
Description: Adenosine is mixed with normal saline up to 20 ml in a single syringe before administering to the patient by the IV bolus method.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-syringe diluted with normal saline technique
Description: Adenosine is mixed with normal saline up to 20 ml in a single syringe before administering to the patient by the IV bolus method.
Study: NCT02510053

Intervention type: DRUG
Group type: OTHER
Intervention: Caspofungin
Description: 40 patients with suspected/preoperation/confirmed IFI in ICU received Caspofungin
Study: NCT01019798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib, docetaxel, cisplatin
Description: 1. Sunitinib given 10 days within 14 days of each cycle。~2. Sunitinib 25 mg/day with adjust dosage according to patient's condition, but should return to 25 mg when feasible or should withdraw from this study.~3. Docetaxel 40-50 mg/m2, cisplatin 50 mg/m2 every 2 weeks.~4. Overall 12 cycles (24 weeks)
Study: NCT03131934

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous EBV-CTL transduced with vector SFG-CNA12
Description: Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the retroviral vector SFG-CNA12 conferring resistance to tacrolimus
Study: NCT03600649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seclidemstat
Description: Twice daily administration of seclidemstat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seclidemstat
Description: Twice daily administration of seclidemstat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seclidemstat
Description: Twice daily administration of seclidemstat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 250 mg/m2/day on Days 1 thru 5 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 0.75 mg/m2/day on Days 1 thru 5 of a 21-day cycle
Study: NCT01700322

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary stenting
Description: All patients will receive a drug eluting stent as clinically indicated.
Study: NCT03131934

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous EBV-CTL transduced with control vector SFG-CNA8
Description: Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the control retroviral vector SFG-CNA8

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leucapheresis
Description: Patients will undergo an unstimulated leucapheresis to isolate the required immune cells to produce the EBV-CTLs
Study: NCT02865811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Please see Arms for description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin (PLD)
Description: Please see Arms for description.
Study: NCT05555316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE combined with Lenvatinib
Description: Three days after the first TACE treatment, when the liver function was evaluated as grade A / B, Lenvatinib was taken orally, 8mg / day (body weight less than 60kg) or 12mg / day (body weight equal to or more than 60kg). Lenvatinib reduction standard: 8mg / day; 4mg / day; 4mg, the next day.
Study: NCT02004327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1029M300mg
Description: DW1029M300mg PO Once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1029M300mg
Description: DW1029M300mg PO Once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1029M300mg
Description: DW1029M300mg PO Once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1029M600mg
Description: DW1029M300mg 2 tablets Once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1029M600mg
Description: DW1029M300mg 2 tablets Once